

References

Agaimy A, Wunsch PH, Hofstaedter F et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. *Am. J. Surg. Pathol.*; 31; 113–120.**2007**

Agaram NP, Besmer P, Wong CC, et al:Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors.*J Clin Cancer Res*, 13(1):170-181.**2007**

Akahoshi K, Yarinobu Sumida, Noriaki Matsui, et al, Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine needle aspiration *World J Gastroenterol* April 14; 13(14): 2077-2082-**2007**

Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. *Ann Surg Oncol*; vol 14(1):14–24.**2007**

Andersson J, Sihto H, Meis-Kindblom, et al. NF1- associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics, *Am J Surg Pathol*, 29(9):1170–1176.**2005.**

Antonescu CR, Sommer G, Sarraf L. et al: Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.*J Clin Cancer Res*;9:3329–3337. **2003**

Antonescu CR, Besmer P, Guo T et al. Acquired resistance to imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation.*J Clin Cancer Res.*; 11; 4182–4190. **2005**

Anthony Padula, Nena W. Chin, PhD, Suleiman Azeez, et al. Primary gastrointestinal stromal tumor of the esophagus in an HIV-positive patient. *Annals of Diagnostic Pathology* 9:49–53. **2005**

Aparicio T, Boige V, Sabourin JC, et al. Prognostic factors after surgery of primary respectable gastrointestinal stromal tumours. *Eur J Surg Oncol*;30(10):1098–103. **2004**

Bang-Bin Chen, Po-Chin Liang, Kao-Lang Liu., et al : Preoperative Diagnosis of Gastric Tumors by Three-dimensional Multidetector Row CT and Double Contrast Barium Meal Study: Correlation with Surgical and Histologic Results: *J Formos Med Assoc* • Vol 106 • No 11. **2007**

Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. *Proceedings of the American Society for Clinical Oncology*;22 [abstract 3271] ,**2003**

Benjamin RS, Blanke CD, Blay JY, et al: Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. *J the Oncologist*;11(1):9-20. **2006**

Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. *J Clin Oncol*;25(9):1107–13. **2007**

Blum MG, Bilimoria KY, Wayne JD, et al. Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors. *Ann Thorac Surg*;84(5):1717–23. **2007**

Burkill GJ, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. *J Radiology*;226(2):527–32. **2003**

Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. *J Mayo Clin Proc*; 74; 543–552. **1999**

Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. *Am. J. Med. Genet.*; 108; 132–139. **2002**

Choi SM, Kim MC, Jung GJ, et al. Laparoscopic wedge resection for gastric GIST: longterm follow-up results. *Eur J Surg Oncol*; 33(4):444–7. **2007**

Chan PM, Ilangumaran S, La Rose J, et al. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. *J Mol Cell Biol* ; 23; 3067–3078. **2003**

Cichoz-Lach H, Kasztelan B, Slomka. Gastrointestinal stromal tumors: epidemiology, clinical picture, diagnosis, prognosis and treatment. *J Pol Arch Med Wewn* ; 118(4):216-221. **2008**

Crosby JA, Catton CN, Davis A, et al. Malignant Gastrointestinal Stromal tumors of the Small intestine: A review of 50 cases from a prospective database. *Annals of Surgical Oncology*; 8:50-9. **2001**

Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. *J. Clin. Oncol.* 22:3813-3825. **2004**

Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *J Clin Oncol.*; 23; 5357–5364. **2005**

Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFR α mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer*;40(5):689–95.**2004**

DeMatteo RP, Lewis JJ, Leung D, et al (): Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg*;231(1):51-58.**2000**

DeMatteo RP, Shah A, Fong Y, et al: Results of hepatic resection for sarcoma metastatic to liver. *Ann Surg*; 234: 540- 547.**2001**

DeMatteo RP, Heinrich MC, El-Rifai WM. et al, Clinical management of gastrointestinal stromal tumors: before and after STI-571. *J Hum Pathol* ; 33: 466–77.**2002**

DeMatteo RP, Owzar K, Maki RG, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. *Proceedings of the American Society for Clinical Oncology* **2007**

DeMatteo R P, Gold J S, Saran L, et al., Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST), *J Cancer* ,112(3):608–615. **2008**

Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med*;347(7):472–80,**2002**

Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* J ; 368: 1329–38.**2006**

Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw;5(Suppl 2):S1–29. **2007**

De Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations,CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. J Pathol Oncol Res ; 9: 13–19.**2003**

Emory TS, Sobin LH, Lukes L, Lee DH, et al: Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol, 23:82-87.**1999.**

Emoke F, Simona M, Doina M,et al,Gastrointestinal stromal tumors:review on morphology, diagnosis and management) Romanian Journal of Morphology and Embryology, 50(3):319–326.**2009**

FLETCHER C D, BERMAN J J, CORLESS C ,et al., Diagnosis of gastrointestinal stromal tumors: a consensus approach,J Hum Pathol, 33(5):459–465.**2002**

Ghanem N, Altehoefer C, Furtwangler A, et al. Computed tomography in gastrointestinal stromal tumors. Eur J Radiol;13(7):1669–78.**2003**

Graham J, Debiec-Rychter M, Corless CL et al. Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation.J Arch Pathol Lab Med; 131; 1393–1396.**2007**

Gold JS and Dematteo RP: Combined surgical and molecular therapy: the gastrointestinal stromal tumor model . Ann Surg;244(2):176-184.**2006**

Gupta P, Tewari M, Shulka H: Gastrointestinal stromal tumor. *J Surg Oncol J* , 17(2):129-138. **2008**

Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol*;21:4342-4349. **2003**

Heinrich MC, Corless CL, Duensing A, McGreevey L, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. *J Science*, 299:708-710. **2003**

Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol*; 24: 4764–74. **2006**

Herrera GA, Cerezo L, Jones JE, et al. Gastrointestinal autonomic nerve tumors: “plexosarcomas.” *Arch Pathol Lab Med*;113:846-853. **1989**

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *J Science* , 279:577-580. **1998**

Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. *J Gastroenterology* ; 122; 1493–1499 . **2002**

Hornick JL, Fletcher CD: The role of KIT in the management of patients with gastrointestinal stromal tumors. *Hum Pathol J* , 38:679-687. **2007**

Jennifer A, Sexton Richard A, Pierce Valerie J, Halpin J, et al: Laparoscopic gastric resection for gastrointestinal stromal tumors, *J Surg Endosc*, 22:2583-2587, **2008**

Joensuu H: Gastrointestinal stromal tumor (GIST). *Annals of Oncology*, **17(10):280-286.2006**

John R. Goldblum, A Review of Characteristic Morphologic, Immunohistochemical, and Molecular Genetic Features: *Am J Clin Pathol*;117 (supl 1)S49-S61:**2002**

Kim CJ, Day s, Yeh K A:Gastrointestinal stromal tumors:analysis of clinical and pathologic factors.*Am j surg*.67:135-137,**2001**

Kim KM, Kang DW, Moon WS, Park JB, et al: Gastrointestinal Stromal Tumor Committee; The Korean Gastrointestinal Pathology Study Group. Incidence and the Clinical, Pathologic and Immunohistochemical Findings. *J Korean Med Sci*, 20:977-984.**2005**

Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumour: gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. *Am J Pathol*; 152: 1259–1269. **1998**

Kinoshita K, Isozaki K, Tsutsui S, Kitamura S, et al: Endoscopic ultrasonography guided fine needle aspiration biopsy in follow-up patients with gastrointestinal stromal tumours. *Eur J Gastroenterol Hepatol*, 15(11):1189-1193.**2003**

Kobayashi K, Gupta S, Trent JC, et al. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. *J Cancer* ; 107: 2833–41.**2006**

Lasota J, Wozniak A, Kopczynski J. et al: Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study of 50 cases.*J Lab Invest*;85:237–247.**2005**

Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). *Semin. Diagn. Pathol J* ; 23; 91–102.**2006**

Lasota J, Miettinen M. KIT exon 11 deletion-inversions represent complex mutations in gastrointestinal stromal tumors. *Cancer Genet. Cytogenet J* ; 175; 69–72.**2007**

Leah Strickland, G. Douglas Letson, and Carlos A. Muro-Cacho. Gastrointestinal Stromal Tumors. *Cancer Control: Journal of the Moffitt Cancer Center* volume, 8 number 3 : page 252-261.**2001**

Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. *J Radiology* ;228(1):235-40.**2003**

Li FP, Fletcher JA, Heinrich MC et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. *J. Clin Oncol.*; 23; 2735–2743.**2005**

Lin SC, Huang MJ, Zeng CY, et al: Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors. *World J Gastroenterology*;9:2809-2812.**2003**

Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications in disease classification and therapy. *J Leuk. Res*; 25; 571–576.**2001**

Lux ML, Rubin BP, Biase TL. et al: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. *Am J Pathol*;156:791–795.**2000**

Maki R, Fletcher JA, Heinrich M, et al. Results from a continuation trial of SU11248(sunitinib) in patient with imatinib resistant gastrointestinal stromal tumor. *Proc Am Soc Clin Oncol*; 24: (Abst 9011)**2005**

Martin J, Poveda A, Llombart-Bosch A. et al: Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research. *J Clin Oncol*;23:6190–6198.**2005**

Mazur MT, Clark HB. Gastric stromal tumours. Reappraisal of histogenesis. *Am J Surg Pathol*; 7: 507–519. **1983**

Medeiros F, Corless C L, Duensing A, et al., KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications, *Am J Surg Pathol*, , 28(7):889–894.**2004**

Miettinen M, Lasota J: Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. *J Virchows Archiv* , 438:1-12.**2001**

Miettinen M, Shekitka K M, SOBIN L H., Schwannomas in the colon and rectum: a clinicopathologic and immunohistochemical study of 20 cases, *Am J Surg Pathol*, ,25(7):846–855.**2001**

Miettinen M, Sarlomo-Rikala M, Sobin L H, Mesenchymal tumors of the muscularis mucosae of colon and rectum are benign leiomyomas that should be separated from gastrointestinal stromal tumors –a clinicopathologic and immunohistochemical study of eighty-eight cases, *J Mod Pathol* , 14(10):950–956.**2001**

Miettinen M, Kopczynski J, Maklout H, et al Gastrointestinal stromal tumors, intramural leiomyomas and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical and molecular genetic study of 167 cases, *Am J Surg Pathol*, , 27(5):625–641.**2003**

Miettinen M, Lasota J, KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation, *J Appl Immunohistochem Mol Morphol*, 13(3):205–220.**2005**

Miettinen M, Sobin L. H, Lasota A J, Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up, *Am J Surg Pathol*, 29(1):52–68.**2005**

Miettinen M, Makhoul H. R, Sobin L, et al, Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up, *Am J Surg Pathol*, 30(4):477–489.**2006**

Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. *Semin. J Diagn. Pathol*; 23; 70–83.**2006**

Motegi A, Sakurai S, Nakayama H, et al, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. *Pathol Int J*, 55:106-112.**2005**

Mohamad El-Zohairy, El-Sayed Ashraf Khlil, Ibrahim Fakhr, et al: Gastrointestinal Stromal Tumor Surgical Treatment, *Journal of the Egyptian Nat. Cancer Inst.*, Vol. 17, No. 2, June: 56-66, **2005**

Nilsson B, Bummig P, Meis-Kindblom JM, et al: Gastrointestinal stromal tumors: The incidence, prevalence, clinical course and

prognostication in the pre- imatinib mesylate era. J Cancer ;103:821-829.**2005**

Nilsson B, Sjolund K, Kindblom LG, et al. Adjuvant imatinib treatment improves recurrence- free survival in patients with high-risk gastrointestinal stromal tumours.Br J Cancer;96(11):1656–8.**2007**

Nishida T, Hirota S. Biological and clinical review of stromal tumours in the gastrointestinal tract.J Histol Histopathol; 15: 1293–1301.**2000**

Novitsky YW, Kercher KW, Sing RF, et al. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg;243(6):738–45.**2006**

Ni Y, Mulier S, Miao Y, et al. A review of the general aspects of radiofrequency ablation. J Abdom Imaging;30:381-400.**2005**

Pantanowitz L, Antonioli DA, Pinkus GS et al. Inflammatory fibroid polyps of the gastrointestinal tract: evidence for a dendritic cell origin. Am J Surg Pathol; 28; 107–114.**2004**

Peter C, Christopher Ryan, John Hart, et al. Surgical treatment of gastrointestinal stromal tumors in the imatinib era.J Surgery ;134:656-66.**2003**

P.J. O’Sullivan, A.C. Harris, S.G. Ho, P.L. Munk. The imaging features of gastrointestinal stromal Tumors. European Journal of Radiology : 1–8,**2006**

Pearson AS, Izzo F, Fleming RY, , et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg;178(6):592-599.**1999**

Pisters PW, Bramwell VH, Rubin BP, O'Sullivan B : Sarcomas of soft tissue. In: , Clinical Oncology :Abeloff MD, Armitage JO, Lichter

AS, Niederhuber JE, Kastan MB, McKenna WG.pa : Elsevier Philadelphia, 3rd ed. ;2608-2609.**2004**

Ponsaing L, Hansen MB: Therapeutic procedures for submucosal tumors in the gastrointestinal tract. World J Gastroenterol, 13(24):3316-22.**2007**

Price VE, Zielenska M, Chilton-MacNeill S et al. Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors . J Pediatr Blood Cancer; 45; 20–24.**2005**

Rajan DK, Soulen MC, Clark TW, et al: Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol; 12: 187- 193.**2001**

Raut CP, Morgan JA, Ashley SW: Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease.J Current Opin Gastroenterol;23(2):149-158.**2007**

Reith JD,Goldblm JR,Lyles RH,Weiss SW:Extra gastrointestinal stromal tumors.An analysis of 48 cases with GIST emphasis on histological predictors of outcome. J Mod Pathol,13,577-585,**2000**.

Roberts WM, Look AT, Ruossel MF et al. Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes. J Cell; 55; 655–661.**1989**

Rosay j. Gastrointestinal stromal tumors.in,surgical pathology: Ackerman, Mosby, 8th ed p.645-7,**1996**

Rosenbaum SJ, Stergar H, Antoch G, Veit P, et al, Staging and follow-up of gastrointestinal tumors with PET/CT. *J Abdom Imaging*; **31**: 25–35. **2006**

Robinson TL, Sircar K, Hewlett BR, et al: Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. *Am J Pathol*, 156, 1157-1163. **2000**

Rubin BP, Antonescu CR, Scott-Browne JP et al. A knock-in mouse model of gastrointestinal stromal tumor harboring Kit K641E. *J Cancer Res.*; 65; 6631–6639 **2006**

Safdar A, Sher A: Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors. *J GENE*, 401:38-45. **2007**

Sakaguchi N, Sano K, Ito M, et al. A case of von Recklinghausen's disease with bilateral pheochromocytoma–malignant peripheral nerve sheath tumors of the adrenal and gastrointestinal autonomic nerve tumors. *Am J Surg Pathol*; 20:889-897.. **1996**

Schneider-Stock R, Boltze C, Lasota J, et al Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. *J Clin Cancer Res*, 11:638-645. **2005**

Seidal T and Edvardsson H, Diagnosis of gastrointestinal stromal tumor by fine-needle aspiration biopsy: a cytological and immunocytochemical study. *J Diagn Cytopathol*; 23(6):397-401. **2000**

Shankar S, Van Sonnenberg E, Desai J, et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. *J Radiology*; 235: 892–98. **2005**

Singer S, Rubin BP, Lux ML, Chen CJ, et al: Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. *J Clin Oncol*, 20:3898-905.**2002**

S Lau, K F Tam, CK Kam, et al, Imaging of gastrointestinal stromal Tumor (GIST). *J Clinical Radiology* : 59, 487–498.**2004**

Steigen SE, Eide TJ, Wasag B, et al: Mutations in gastrointestinal stromal tumors-a population-based study from Northern Norway. *J of Acta Pathologica, microbiologica et Immunologica (APMIS)*, 115:289-298.**2007**

Takazawa Y, Sakurai S, Sakuma Y, et al:Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). *Am. J. Surg. Pathol*; 29; 755–763.**2005**

Taniguchi M, Nishida T, Hirota S, et al :Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. *J Cancer Res*;59:4297–4300.**1999**

Tran T, Davila JA, El-Serag HB: The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992 to 2000. *Am J Gastroenterol*, 100:162-168.**2005**

Tsukuda K, Hirai R, Miyake T, et al:The outcome of gastrointestinal stromal tumors after a surgical resection in our institute. *J Surgery today*, 37:953-957.**2007**

Van der Zwan SM and DeMatteo RP: Gastrointestinal stromal tumor: 5 years later. *J Cancer*;104:1781-1788.**2005**

Van G M, Verweij J, Casali PG, et al: Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. *J Clin Oncol*;23(24): 5795–804, **2005**

Van Oosterom AT, Judson I, Verweij J, et al: European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib in metastatic gastrointestinal stromal tumours: a phase I study. *J Lancet*,358:1421-1423.**2001**

Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.*J Lancet*;364(9440):1127–34.**2004**

Wang L, Vargas H, French SW. Cellular origin of gastrointestinal stromal tumours: a study of 27 cases.*J of Archives of Pathology & Laboratory Medicine*; 124: 1471–1475.**2000**

Wardelmann E, Hrychyk A, Merkelback-Bruse S. et al: Association of platelet-derived growth factor receptor alpha mutations with gastric primary site an epithelioid or mixed cell morphology in gastrointestinal stromal tumors. *J Mol Diagn*;6:197–204.**2004**

Wayne JD, Bell RH Jr. Limited gastric resection. *Surg Clin North Am*;85(5):1009–20,**2005**.

Winfield RD, Hochwald SN, Vogel SB, et al. Presentation and management of gastrointestinal stromal tumors of the duodenum. *Am J Surg*;72(8):719–22.**2006**

Xie Hong, Haesua Choi, Erellyne M,et al.,Gastrointestinal Stromal Tumor:Role of CT in Diagnosis and in Response Evaluation and Surveillance after Treatment with Imatinib, Radiographic the journal of continuing medical education in radiology:26,481-495,**2006**

Yantiss R K, Rosenberg A E, Sarran L ,et al. Multiple Gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study.J Mod Pathol; 18; 475–484.**2005**

Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer; 41: 1751–57.**2005**

Zoller ME, Rembeck B, Oden A, et al: Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population.J Cancer; 79; 2125–2131. **1997**